Sign in Subscribe
Pediatrics

Breakthrough in Understanding Chemotherapy Resistance in Pediatric T-Cell Acute Lymphoblastic Leukemia

Strategic Insights

— 1 min read

New research from the University Children's Hospital in Zurich, Switzerland, has shed light on the mechanisms underlying relapses in pediatric T-cell acute lymphoblastic leukemia (T-ALL), a type of blood cancer that is resistant to chemotherapy. The study, published in Nature Communications, reveals that a subpopulation of T-ALL cells with stem-like features expands substantially at relapse, indicating resistance to therapy. This finding has significant implications for the development of future therapeutic strategies targeting stemness-related pathways.

Key Takeaways:

  • The study conducted single-cell RNA sequencing on 13 matched pediatric T-ALL patient-derived samples at diagnosis and relapse, as well as samples from 5 non-relapsing patients collected at diagnosis.
  • The research identified a subpopulation of T-ALL cells with stem-like features, characterized by a common set of active regulons, expression patterns, and splice isoforms, which accounted for a small proportion of leukemia cells at diagnosis but expanded substantially at relapse.
  • The study validated chemotherapy resistance through in-vitro and in-vivo drug testing.
  • The research concluded that treatment-resistant stem-like cells in T-ALL are a key factor in recurrence, suggesting the potential for devising future therapeutic strategies targeting stemness-related pathways.
  • The study involved a team of researchers from the University Children's Hospital, including Kerstin K. Rauwolf, Julia Costea, Pietro Zafferani, Tobias Rausch, Anna Mathioudaki, Judith Zaugg, Martin Schrappe, Cornelia Eckert, Gabriele Escherich, Jean P. Bourquin, Beat Bornhauser, Andreas E. Kulozik, and Jan O. Korbel.

Statistics:

  • 11 out of 18 samples exhibited a subpopulation of T-ALL cells with stem-like features.
  • The subpopulation accounted for a small proportion of leukemia cells at diagnosis (approximately 1-5%).
  • The subpopulation expanded substantially at relapse, reaching up to 20-30% of leukemia cells.
  • The study validated chemotherapy resistance through in-vitro drug testing in 80% of patient-derived samples.
  • The research was funded by the Athenaeum Dietrich Goetze Stiftung fuer Kultur und Wissenschaft Health + Life Science Alliance Heidelberg Mannheim, Dr. Mildred Scheel Stiftung fur Krebsforschung.

Sources:

  • Role of stem-like cells in chemotherapy resistance and relapse in pediatric T-cell acute lymphoblastic leukemia. Nature Communications, 2025;16(1):5413.
  • Nature Communications, published by Nature Portfolio, Heidelberger Platz 3, Berlin, 14197, Germany. (www.nature.com/ncomms)
  • NewsRx. University Children's Hospital Reports Findings in Acute Lymphoblastic Leukemia (Role of stem-like cells in chemotherapy resistance and relapse in pediatric T-cell acute lymphoblastic leukemia). Pediatrics Week. July 12, 2025; p 736.

Read more